Wegovy
PulseAugur coverage of Wegovy — every cluster mentioning Wegovy across labs, papers, and developer communities, ranked by signal.
6 day(s) with sentiment data
-
GLP-1 Drugs Boost Women's Employment More Than College Degrees, Study Finds
A study from Harvard University, published by the National Bureau of Economic Research, suggests that GLP-1 drugs, such as Ozempic and Wegovy, have a greater impact on increasing women's employment rates than obtaining …
-
Bank of America spends $250M annually on weight loss drugs for staff
Bank of America is significantly investing in employee wellness by spending over $250 million annually on weight loss drugs like Ozempic and Wegovy. CEO Brian Moynihan views this as a crucial investment in employee heal…
-
Companies tap retired CEOs amid succession planning crisis
Companies are increasingly turning to retired CEOs to fill leadership gaps as internal succession pipelines become depleted. This trend is driven by executives staying in their roles longer, leading to potential success…
-
Novo Nordisk faces growth challenges after Wegovy success, rival Eli Lilly gains ground
Novo Nordisk, once Europe's most valuable company due to the success of its weight-loss drugs Ozempic and Wegovy, is facing challenges in developing new blockbuster treatments. Its rival, Eli Lilly and Company, has gain…
-
GLP-1 drugs like Ozempic may cause unlisted side effects, study finds
New research indicates that GLP-1 medications like Ozempic and Wegovy may have side effects not listed on their labels. A study analyzing Reddit posts found that nearly half of semaglutide and tirzepatide users reported…
-
Medicare launches GLP-1 bridge program for weight loss drugs
The Medicare Bridge program, initiated by the Trump administration, offers eligible seniors and disabled individuals access to certain GLP-1 weight loss medications for a flat $50 monthly co-payment. This demonstration …
-
FDA peptide vote could unlock new telehealth market, mirroring Ozempic boom
The FDA's upcoming vote on seven peptides, including BPC-157 and TB-500, could legitimize a new multibillion-dollar market for wellness injectables. Telehealth companies like Hims & Hers, which previously profited from …
-
Medicare launches $50/month GLP-1 weight loss drug program
The Trump administration has launched a temporary Medicare Bridge program to provide some beneficiaries with access to popular weight loss medications like tirzepatide and semaglutide for a flat $50 monthly co-payment. …
-
GLP-1 drugs disrupt diet trends, fueling protein-focused food market
GLP-1 medications are fundamentally altering the food industry, according to David Protein CEO Peter Rahal. He states that traditional diet trends are becoming obsolete as people increasingly turn to these drugs for wei…
-
Medicare to offer weight-loss drugs, straining doctor capacity
Starting next month, Medicare will offer weight-loss drugs like Wegovy and Zepbound for a subsidized price of $50 per month. This initiative is expected to lead to a significant surge in demand, potentially overwhelming…
-
GLP-1 Drugs Could Save Adults Hundreds of Thousands in Medical Costs
A new study from the National Bureau of Economic Research (NBER) suggests that middle-aged adults using GLP-1 drugs for obesity could save over $192,000 in lifetime medical costs. These savings are even higher for indiv…
-
Novo Nordisk hit by cyberattack stealing clinical trial data
Novo Nordisk has reported a cyberattack where hackers stole clinical trial data. The company is investigating the incident, which occurred around the same time the UK approved Wegovy for weight management. This attack h…
-
Health plans balk at paying for GLP-1 weight loss drugs
Health plans and employers are increasingly hesitant to cover GLP-1 drugs for weight loss due to high costs and patient discontinuation rates. A new report indicates that nearly half of employers not currently covering …
-
Eli Lilly launches direct-to-consumer drug sales bypassing PBMs
Eli Lilly has launched LillyDirect, a direct-to-consumer platform for its weight-loss medications like Zepbound, bypassing traditional pharmacy benefit managers (PBMs). This integrated system includes online physician r…
-
Novo Nordisk CEO eyes longevity and aesthetics beyond weight loss drugs
Novo Nordisk's CEO, Mike Doustdar, is exploring new therapeutic areas beyond weight loss and diabetes, including longevity and aesthetic medicine. The company is investigating semaglutide's potential to protect vital or…
-
Government healthcare cost projections struggle with GLP-1 drug spending
Government healthcare cost projections for GLP-1 medications like Ozempic and Mounjaro are proving difficult to accurately forecast. Agencies like CMS and CBO rely on historical data and assumptions that may not account…
-
Peptide gray market increasingly uses crypto for transactions
A growing gray market for peptides, used for wellness and the "looksmaxxing" trend, is increasingly relying on cryptocurrency for transactions. Vendors in this space face challenges with traditional payment processors d…
-
Withings launches $280 smart scale for GLP-1 users
Withings has released the BodyFit, a new smart scale priced at $280, specifically designed for users of GLP-1 weight loss medications. This scale aims to help users monitor muscle mass loss, a common side effect of thes…
-
France to reimburse anti-obesity drugs for first time in EU
France is set to become the first European Union country to reimburse anti-obesity medications for severely obese patients starting mid-June. The government estimates this initiative will cost approximately €100 million…
-
GLP-1 drugs show anti-inflammatory benefits beyond weight loss
GLP-1 medications like Ozempic and Wegovy, known for weight loss, are showing promise in treating inflammation and tissue damage, particularly in osteoarthritis. A study in Cell Metabolism found semaglutide reduced infl…